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Objectives: Tuberculosis drug development is hampered by the slow growth of Mycobacterium tuberculosis.
Bioluminescence, light produced by an enzymatic reaction, constitutes a rapid and highly sensitive measure-
ment of cell metabolic function that can be used as an indirect marker of cell viability in drug screening
assays. The aim of this work was to validate and standardize the use of luminescent M. tuberculosis strains
to test the activity of antibacterial drugs in vitro and inside macrophages in a 96-well format.
Methods: We have used strains that express the bacterial lux operon and therefore do not require exogenous
substrate to produce light, as well as strains expressing the firefly luciferase that need luciferin substrate.
Results were compared with those obtained using the resazurin reduction assay and cfu plating.
Results: Using bioluminescence we were able to reduce the time required to measure the MIC and bactericidal
concentrations of antimicrobials to just 3 and 6 days, respectively. Furthermore, antibacterial activity against
intracellular mycobacteria was detected within 2 days post-infection. Results were comparable to those
obtained by conventional methods.
Conclusions: We have developed a simple and rapid method for screening antimycobacterial drugs in culture
and in macrophages. The use of autoluminescent bacteria also facilitates the determination of growth and
inhibition kinetics. The method is cost-effective, can easily be adapted to a larger scale and is amenable to
automation. Current efforts are directed towards applying this technology to drug screening in vivo.
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Introduction
Tuberculosis still constitutes a serious global health threat with
9.4 million new cases and 1.7 million deaths worldwide in
2009.1 There is also a huge reservoir of infection, since an esti-
mated one-third of the world’s population is infected with its
causative agent, Mycobacterium tuberculosis. The main handicaps
in fighting tuberculosis are the BCG vaccine, which works poorly in
the most affected populations, and a treatment regimen that
takes 6 months with up to four drugs for the active disease and
up to 9 months for eradicating latent infection. This is further
complicated by multidrug-resistant and extensively drug-resistant
strains, requiring even longer treatment times with even less well-
tolerated drugs. It is clear then, that new drugs targeting both
active and latent infections are urgently needed.
The main steps followed by most tuberculosis whole cell-
based drug screening programmes consist of a quick initial
screening at one fixed concentration, subsequent MIC deter-
mination for the best hits, followed by antimycobacterial
activity testing in macrophages for those compounds that
have been shown to lack eukaryotic cytotoxicity and, finally,
in vivo testing in animal models.2,3 Sometimes, additional
assays are carried out, such as determination of the MBC or
activity testing against drug-resistant clinical isolates to
assess for cross-resistance.3 This already extended protocol
becomes even longer due to the slow growth of M. tuberculosis,
which divides every 24 h and needs 3–4 weeks to form
colonies on solid medium. Therefore, methods able to rapidly
detect mycobacterial growth are preferred. The most popular
methods for drug testing and MIC determination are redox-
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based techniques, including the microplate Alamar Blue assay,
the resazurin microplate assay (REMA) and assays based on
tetrazolium dyes.4–6 These methods have turnaround times
of 7–9 days, and their main advantage is that they are colori-
metric and therefore results can easily be determined by visual
inspection. Besides, a more quantitative and objective result
can be obtained by performing colorimetric or fluorometric
measurements using a plate reader, which is also more sensi-
tive and can therefore shorten the turnaround time. An alter-
native microdilution plate assay involves the
spectrophotometric measurement of optical density (OD) to
assess growth inhibition.7 This requires special equipment,
but is faster (3–5 days) and does not require the addition of
any reagents. An additional advantage is that measurements
are non-destructive and can be taken at various timepoints,
producing kinetic data that can be used to plot dose–response
curves and calculate effective concentrations more precisely.
However, none of these methods is suitable for drug testing
inside macrophages, which relies on time-consuming cfu-
based methods. In contrast, reporter strains that express
either a fluorescent protein or a luciferase can be used for
drug testing both in vitro and in cell-based systems, such as
macrophages.8–11 This is particularly true for luciferase
assays, since luminescence produces a higher signal-to-
background ratio than fluorescence measurements. Moreover,
luminescent strains can be used for non-invasive drug assess-
ment in animal models by in vivo imaging12–16 or by measur-
ing light production in organ homogenates.17
Two luciferases have been used in mycobacterial research:
the firefly luciferase (FFluc) and the bacterial luciferase of
Vibrio harveyi (LuxAB). These luciferases produce light in the
presence of the substrate/co-factor combinations D-luciferin/
ATP and n-decanal/FMNH2, respectively. These co-factors are
only found in live cells and so light production provides a sen-
sitive indicator of cell viability. A major advantage of the bac-
terial luciferase system is that the genes for the synthesis of
the substrate have also been described; the expression of
the whole operon (luxCDABE) renders the bacteria autolumi-
nescent, i.e. no external addition of substrate is needed for
light production. However, until recently, only the bacterial
luciferase enzyme (LuxAB) on its own had been successfully
used in mycobacteria. Therefore, the drug screening protocols
developed so far in mycobacteria, with either of the two luci-
ferases, required the addition of substrate, making them de-
structive, endpoint measurements. In previous work, we
described for the first time the successful expression in myco-
bacteria of the whole lux operon from Photorhabdus lumines-
cens.18 Furthermore, we optimized the expression of both lux
and ffluc, and we proved that these reporters are suitable
for in vivo imaging of mycobacteria. In the present study,
we have validated and standardized the use of
luciferase-expressing M. tuberculosis for drug testing in vitro
and inside macrophages. We have used both the Lux operon
and FFluc enzyme, since the latter is brighter, even though it
requires the addition of substrate. We prove that, using bio-
luminescence, MICs and MBCs are obtained in just 3 and
6 days, respectively, and that antibacterial activity in
macrophages is detected as early as 1–2 days post-infection,
with results comparable to those obtained by traditional
methods. Furthermore, we show that this method can be
applied to clinical isolates and, therefore, could be used to
test cross-resistance using drug-resistant isolates.
Materials and methods
Strains and growth conditions
The M. tuberculosis strains used in this study are described in Table 1.
All strains were grown at 378C on Middlebrook 7H11 agar medium
(BD Diagnostics) supplemented with 0.5% glycerol and 10%
oleic acid-albumin-dextrose-catalase (OADC) (BD Diagnostics) or in
Middlebrook 7H9 broth (BD Diagnostics) containing 0.05% Tween 80,
0.2% glycerol and 10% OADC. When required, kanamycin was used at
a final concentration of 25 mg/L. For the drug testing assays, Middlebrook
7H9 medium was prepared without Tween or kanamycin. Bacterial
strains were kept as frozen stocks at 2808C in 10% glycerol. The stocks
were inoculated into 10 mL of medium and incubated for 7–10 days in
a shaking incubator. Cultures were then diluted 1/100 into fresh
medium and grown to mid-log phase (4–5 days) prior to being used in
drug testing or infection assays.
Table 1. Strains used in this study
Strain Description Reference
H37Rv hsp M. tuberculosis strain H37Rv transformed with
the integrating expression vector
pMV306hsp, Kanr
18
H37Rv
LuxG13
M. tuberculosis strain H37Rv transformed with
the bacterial luciferase-encoding vector
pMV306hsp+LuxAB+G13+CDE, Kanr
18
H37Rv
hspFFluc
M. tuberculosis strain H37Rv transformed with
the firefly luciferase-encoding vector
pMV306hsp+FFluc, Kanr
18
212 hsp M. tuberculosis Beijing strain 212 transformed
with the integrating expression vector
pMV306hsp, Kanr
this work
212 LuxG13 M. tuberculosis Beijing strain 212 transformed
with the bacterial luciferase-encoding vector
pMV306hsp+LuxAB+G13+CDE, Kanr
this work
232 hsp M. tuberculosis clinical isolate 232 from the
Indo-Oceanic lineage transformed with the
integrating expression vector pMV306hsp,
Kanr
this work
232 LuxG13 M. tuberculosis clinical isolate 232 from the
Indo-Oceanic lineage transformed with the
bacterial luciferase-encoding vector
pMV306hsp+LuxAB+G13+CDE, Kanr
this work
355 hsp M. tuberculosis strain 355 belonging to the
Euro-American lineage transformed with the
integrating expression vector pMV306hsp,
Kanr
this work
355 LuxG13 M. tuberculosis strain 355 belonging to the
Euro-American lineage transformed with the
bacterial luciferase-encoding vector
pMV306hsp+LuxAB+G13+CDE, Kanr
this work
Kanr, kanamycin resistant.
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Antimicrobial agents
Isoniazid, chloramphenicol, streptomycin, ethambutol, rifampicin and
levofloxacin were all from Sigma. Isoniazid, streptomycin, ethambutol
and levofloxacin were dissolved in water, whereas chloramphenicol
was prepared in ethanol and rifampicin in DMSO. Aliquots of each drug
were kept at 2208C and thawed just before use. For the MIC/MBC
assays, drugs were diluted to the working concentration in Middlebrook
7H9 supplemented with 0.2% glycerol and 10% OADC. The drug concen-
trations tested ranged from 0.008 to 0.25 mg/L for isoniazid, 2.5 to
80 mg/L for chloramphenicol, 0.125 to 4 mg/L for streptomycin, 0.5
to 16 mg/L for ethambutol, 0.008 to 0.25 mg/L rifampicin and 0.062 to
2 mg/L for levofloxacin.
MIC determinations
Drug activity was tested by REMA6 and bioluminescence assays.
REMA
Twofold serial dilutions were made in Middlebrook 7H9medium in 96-well
opaque white plates (Corningw) in duplicate. An inoculum at an OD600 of
0.01 was prepared by diluting mid-log cultures into 10 mL of medium
and 100 mLwas added per well (102–103 cfu). Growth controls containing
no drug and a sterile control without bacteria were also prepared for each
assay. To prevent sample evaporation during incubation, 200 mL of sterile
water was added to all outer perimeter wells. The plates were incubated
at 378C for 7 days before adding 30 mL of sterile 0.01% resazurin to the
growth control wells and incubating for a further 24 h. A change in
colour from blue (oxidized state) to pink (reduced state) indicated
growth of the bacteria and resazurin was added to all remaining wells.
After 24 h, the visual MIC was determined as the lowest drug
concentration that prevented growth and, therefore, colour change.
Bioluminescence assay
The same plates prepared for REMA were used for the bioluminescence
assay. For strains expressing the lux operon, bioluminescence was mea-
sured for 10 s using a microplate reader (Luminoskan Ascent, Thermo Sci-
entific). Bioluminescence was expressed as relative light units (RLU). For
strains expressing the firefly luciferase, a 10 mL sample from each well
was transferred to a new plate containing 40 mL of Middlebrook 7H9
medium and bioluminescence was read for 10 s after injecting 50 mL of
300 mg/L luciferin. Bioluminescence was read after 2, 3, 4, 5, 7 and
8 days of incubation. Cultures of the luciferase-negative M. tuberculosis
(hsp) were processed in parallel and the measurements were treated
as background luminescence. The MIC was defined as the lowest
antibiotic concentration that resulted in a 1 log reduction in
bioluminescence compared with no-drug controls (growth controls).
MBC determinations
At days 3 and 8 of incubation, 5 mL from each well of the MIC plates
was transferred to a plate containing 195 mL per well of drug-free
Middlebrook 7H9 medium. The presence of viable bacteria was then
tested by three methods: cfu; bioluminescence; and resazurin. For cfu,
20 mL from each well of the MBC plate was dropped on Middlebrook
7H11 plates that were incubated for up to 4 weeks. For the biolumines-
cence method, the MBC plates were incubated at 378C and biolumines-
cence was read on days 2, 3, 4, 7 and 8, as described for the MIC
plates. For the resazurin method, 30 mL of sterile 0.01% resazurin was
added to the growth control wells on days 3 or 7 and the plates
were incubated for another 24 h; resazurin was then added to the
remaining wells if a change in colour had occurred in the control
wells. For each of the three methods, the MBC was defined as the
lowest antibiotic concentration that resulted in the killing of ≥99% of
the bacteria in comparison with the starting inoculum, with a
luminescence less than or equal to the background, or which prevented
a colour change of the resazurin, respectively. The compound was
considered bactericidal when the MBC/MIC ratio was ≤4.
Macrophage assays
The intracellular activity of the drugs was evaluated in J774 cells (ATCC
TIB-67TM), as reported previously for mycobacteria,19–22 but with some
modifications. J774 cells were maintained in Dulbecco’s minimal essen-
tial medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum. The cells were plated at a concentration of 5×104 cells
per well in 96-well tissue culture white plates with clear bottoms
(Corningw) and allowed to adhere overnight. For the infection, mid-log
phase M. tuberculosis were washed twice with PBS+0.05% Tween,
once with Dulbecco’s PBS and then sonicated for 2×30 s in a bath soni-
cator. The bacteria were then diluted in DMEM and added to the J774
cells at a concentration of 5×105 cfu/well. After 4 h of infection at
378C in 5% CO2, macrophages were treated with 200 mg/L amikacin
for 30 min and washed thrice with DMEM to eliminate any extracellular
bacteria. Lastly, 200 mL of complete DMEM, with or without antimycobac-
terial drugs, was added to each well. The concentrations tested for each
drug were 0.25×, 1×, 4× and 16× MIC. Each drug concentration was
tested in triplicate. Macrophages were observed periodically under the
microscope to check for viability and the presence of extracellular
bacteria. The medium was changed on day 4.
Bacterial viability was assessed by cfu enumeration and by measuring
bioluminescence. Macrophages were lysed with sterile water for 30 min,
serially diluted in PBS–Tween and 20 mL was dropped onto Middlebrook
7H11 plates for viable count determination. The cfu were plated just
after the infection (day 0) and at the end of the experiment. Biolumines-
cence from strains expressing the lux operon was measured in whole
macrophages for 10 s using a microplate reader (Luminoskan Ascent,
Thermo Scientific). For strains expressing the firefly luciferase, a 50 mL
sample from the macrophage lysate was transferred to a new plate
and bioluminescence was read for 10 s after injecting 50 mL of
300 mg/L luciferin. Bioluminescence for the Lux strains was measured
on days 0, 1, 2, 4 and 7 post-infection, whereas for the FFluc strains it
was measured on days 0 and 7. Data were expressed as the percentage
growth inhibition, i.e.
100− cfus or RLUs in infected cellswith drugs
cfus or RLUs in infected cellswith nodrugs
× 100
( )
,
and was plotted as a function of drug dose. The effective concentration
that caused 90% inhibition (EC90) was determined using sigmoidal
dose–response (variable slope) non-linear regression, with a special
concentration–response function called ‘log (agonist) vs. response—
Find ECanything’ in GraphPad Prism 5.02 (GraphPad Software, CA, USA).
Statistical analysis
The results of the macrophage assays are aggregates of two or three
independent experiments. To compare the dose–response curves
obtained using the cfu method versus the bioluminescence method,
GraphPad Prism was used to compare two models. In the first model
(null hypothesis), the data were fitted with the assumption that the
datasets for the two methods shared the same best-fit value of log
EC90. In the second model (alternative hypothesis), the data were
fitted with the assumption that the best-fit values of log EC90 were dis-
tinct. The models were then compared with the extra sum-of-squares
F-test.23 Values of P,0.05 were considered significant for all
comparisons.
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Results
Use of bioluminescence to determine MICs in vitro
Tovalidate theuseof bioluminescence toassessantimycobacterial
drug activity, the in vitro activities of six different drugs were
evaluated and compared with the MIC data obtained using the
published REMA method.6 We chose antibiotics with different
mechanisms of action: isoniazid, which affects mycolic acid
synthesis and is bactericidal; chloramphenicol, which inhibits
protein synthesis by binding to the 50S ribosomal unit and is
bacteriostatic; streptomycin, which affects protein synthesis by
binding to the30S ribosomal unit andhasabactericidal effect; eth-
ambutol, which interferes with the synthesis of the arabinogalac-
tan and is bactericidal; rifampicin, which inhibits transcription
and is bactericidal; and levofloxacin, which affects DNA synthesis
and is bactericidal. The experiments were initially donewith the la-
boratory strain H37Rv using two bioluminescent reporters: Lux and
FFluc. The plates were read daily to monitor the kinetics of bio-
luminescence production by H37Rv LuxG13 in the presence of
2-fold dilutions of antimicrobial agents. Examples of this are
shown for isoniazid, chloramphenicol and streptomycin in
Figure 1. An effect of the antibiotic could already be observed on
day 2 and the dose–response curves were similar for all the time-
points tested (Figure 1). Equivalent results were obtained when
using H37Rv hspFFluc, although a higher variability was observed,
most likely as a result of the pipetting error introducedwhilemeas-
uring the luminescence of FFluc. For both reporters, theMIC results
were available in 2–3 days, compared with 8 days required with
REMA, and the median MICs for the six drugs differed by no more
than one dilution comparing the bioluminescence and REMA
methods (Tables 2 and 3).
To test if this method could also be used with M. tuberculosis
strains other than the laboratory strain H37Rv, we assayed the
activity of isoniazid and chloramphenicol against three clinical
isolates transformed with the lux operon. As for H37Rv, the
results for the clinical isolates were obtained in just 2–3 days
using the luciferase assay and the median MICs differed by no
more than one drug concentration compared with those
obtained using the REMA method (Table 4).
As expected, the expression of lux or ffluc did not affect
the drug sensitivity of M. tuberculosis, since the MICs for the
bioluminescent strains were not significantly different from
those for the same strains carrying the empty vector
(Tables 2–4).
Use of bioluminescence to determine MBCs in vitro
To our knowledge, the only method reported so far to measure
MBCs in M. tuberculosis has been plating samples to count cfu,
which can take up to 4 weeks because of the slow growth of
this bacterium. Therefore, we wanted to develop a faster
method using bioluminescence. We reasoned that if the drugs
being tested had killed the bacteria we would not see an increase
in bioluminescence upon subsequent transfer of the cells to
medium with no drug. Whereas with bacteriostatic drugs,
bacterial growth and bioluminescence would recover once the
drug was removed.
To test this, samples were transferred from the MIC assay to
new plates containing antibiotic-free medium and incubated
for either 3 or 8 days, leading to a total turnaround
(MIC+MBC) of 6 and 16 days, respectively. The results for isoni-
azid, chloramphenicol and streptomycin for plates incubated
for 3 days and using H37Rv LuxG13 can be seen in Figure 2. In
the case of isoniazid and streptomycin, upon transferring the
cells to drug-free medium, an increase in bioluminescence was
observed in the wells that had been inoculated with cells from
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Figure 1. Effect of isoniazid (INH), chloramphenicol (CHL) and streptomycin (STR) on bioluminescence of H37Rv LuxG13 expressed as a function of
time for all the concentrations tested (top graphs), and as a dose–response curve after 2–8 days of incubation (bottom graphs). The vertical
dotted line in the dose–response curves indicates the MIC measured using the bioluminescence results. Data shown are the mean and standard
deviation from one representative experiment.
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Table 3. MICs (mg/L) of six antimicrobial agents against H37Rv hsp and H37Rv hspFFluc, as determined with the REMA and bioluminescence methods
Drug
Bioluminescence REMA
day 2 day 3 day 4 day 7 day 8 hspFFluc hsp
INH 0.25 (0.25) 0.062 (0.031–0.062) 0.031 (0.062) 0.031 (0.031) 0.031 (0.031–0.062) 0.062 (0.062) 0.062 (0.031–0.062)
CHL 5 (2.5–10) 5 (2.5–5) 2.5 (2.5–10) 5 (2.5–5) 10 (5–10) 5 (5) 5 (5)
STR 0.5 (0.25–0.5) 0.25 (0.125–0.5) 0.125 (0.125–0.5) 0.25 (0.125–0.5) 0.5 (0.25–0.5) 0.25, 0.5a 0.25, 0.5a
EMB 2 (2) 2 (1–2) 2 (0.5–2) 2 (1–2) 2 (2) 2 (1–2) 1.5 (1–2)
RIF 0.031 (0.016–0.062) 0.016 (0.008–0.031) 0.016 (0.016–0.062) 0.031 (0.031) 0.016 (0.016) 0.062 (0.031–0.062) 0.031 (0.031–0.062)
LVX 0.25 (0.125–0.5) 0.25 (0.125–0.25) 0.25 (0.125–0.25) 0.25 (0.125–0.25) 0.25 (0.25) 0.25 (0.125–0.25) 0.25 (0.125–0.25)
INH, isoniazid; CHL, chloramphenicol; STR, streptomycin; EMB: ethambutol; RIF, rifampicin; LVX, levofloxacin.
Results for REMA were read on day 9, whereas bioluminescence results were read at different times from day 2 to day 8.
Results are expressed as the median and range (minimum–maximum) of 3–5 independent experiments.
aEach value was obtained in two out of four experiments.
Table 2. MICs (mg/L) of six antimicrobial agents against H37Rv hsp and H37Rv LuxG13, as determined with the REMA and bioluminescence methods
Drug
Bioluminescence REMA
day 2 day 3 day 4 day 5 day 7 day 8 LuxG13 hsp
INH 0.031 (0.031–0.062) 0.031 (0.031) 0.031 (0.031) 0.031 (0.031) 0.031 (0.031–0.062) 0.031 (0.031–0.062) 0.031 (0.031) 0.031 (0.031)
CHL 10 (5–10) 10 (5–10) 10 (5–10) 10 (10) 10 (5–10) 10 (10) 5 (5) 5 (5)
STR 0.5 (0.5–1) 0.5 (0.5) 0.5 (0.5) 0.5 (0.5) 0.5 (0.5) 0.5 (0.5–1) 0.5 (0.25–0.5) 0.5 (0.25–0.5)
EMB 2 (2) 2 (1–2) 2 (1–2) 2 (2) 2 (1–2) 2 (2) 2 (1–2) 2 (1–2)
RIF 0.062 (0.016–0.062) 0.031 (0.031–0.062) 0.031 (0.016–0.031) ND 0.062 (0.031–0.062) 0.062 (0.062) 0.031 (0.031–0.062) 0.031 (0.031–0.062)
LVX 1 (0.5–2) 0.25 (0.125–0.25) 0.25 (0.125–0.25) ND 0.25 (0.125–0.25) 0.25 (0.125–0.25) 0.25 (0.125–0.25) 0.25 (0.125–0.25)
ND, not determined; INH, isoniazid; CHL, chloramphenicol; STR, streptomycin; EMB, ethambutol; RIF, rifampicin; LVX, levofloxacin.
Results for REMA were read on day 9, whereas bioluminescence results were read at different times from day 2 to day 8.
Results are expressed as the median and range (minimum–maximum) of 3–5 independent experiments.
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the lower inhibitory drug concentrations in the MIC plate,
whereas luminescence remained below the background in
samples coming from higher drug concentration wells. The
MBC for these two antibiotics is thus twice the MIC (MBC/MIC
ratio¼2) and, therefore, they would be classified as bactericidal
drugs, which agrees with the literature.24,25 In the case of chlor-
amphenicol, bioluminescence increased in all samples except
those coming from the highest drug concentrations tested
(Figure 2), giving an MBC/MIC ratio of 8, which is in agreement
with chloramphenicol being a bacteriostatic drug.
Because similar results were obtained for plates incubated for
3 days and those incubated for 8 days (data not shown), we
decided to perform the rest of the experiments with incubation
times of 3 days, since the turnaround was shorter. A summary
of the MBC results obtained for H37Rv LuxG13 is shown in
Table 5. MBCs were calculated by measuring bioluminescence
on days 2–4, or by adding resazurin on days 3–4 and plating
for cfu counts. More interexperiment variability was observed
for the MBC than for the MIC, regardless of the method employed
to determine the MBC. This is probably due to low bacterial
numbers and it could be addressed by increasing the initial
inoculum. This was particularly problematic when using FFluc
as the bioluminescent reporter (data not shown), because of
the added variability introduced when taking samples to read
the luminescence. Nevertheless, the MBCs obtained by measur-
ing the luminescence from the Lux reporter differed by no
more than one drug concentration from those obtained with
the traditional cfu method (Table 5). We also tried using resazurin
to read the MBCs plates; however, the results were difficult to
interpret and the MBCs obtained were much lower than those
calculated with any of the other two methods (Table 5), suggest-
ing that resazurin is not sensitive enough to detect low growth.
In summary, measuring the luminescence from lux-
expressing M. tuberculosis that had been incubated for 3 days
in the presence of drugs and thereafter transferred to drug-free
medium for a further 3 days allows the determination of the MBC
in a total time of 6 days, with results equivalent to those
obtained by the traditional time-consuming cfu plating method.
Drug susceptibility testing inside macrophages
To investigate the feasibility of using bioluminescence to assess
intracellular antimycobacterial drug activity, J774 macrophages
were infected with luminescent and control M. tuberculosis
H37Rv and exposed to various antibiotic concentrations.
Bacterial viability was assessed by cfu enumeration and by
bioluminescence reading. Four antibiotics were tested: isoniazid;
chloramphenicol; streptomycin; and levofloxacin. The cfu and
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Figure 2. Bioluminescence of H37Rv LuxG13 incubated for 3 days in the presence of the indicated antimicrobial agents (MIC plates), followed by
incubation in the absence of antibiotics (MBC plates). The vertical dotted line indicates the time when the antibiotic was removed. Data shown are
the mean and standard deviation from one representative experiment. Bioluminescence was corrected for the dilution applied to set up the MBC
plates. Readings for the non-luminescent H37Rv hsp strain represent the background bioluminescence, which is indicated as the shaded area.
INH, isoniazid; CHL, chloramphenicol; STR, streptomycin.
Table 4. MICs (mg/L) of isoniazid and chloramphenicol against M. tuberculosis clinical isolates 212 LuxG13, 212 hsp, 232 LuxG13, 232 hsp,
355 LuxG13 and 355 hsp, as determined with the REMA and bioluminescence methods
Strain/drug
Bioluminescence REMA
day 2 day 3 day 4 day 5 day 7 day 8 LuxG13 hsp
212INH 0.062 (0.062) 0.031, 0.062a 0.031 (0.031) 0.031 (0.031) 0.031 (0.031) 0.031 (0.031) 0.062 (0.062) 0.062 (0.062)
212CHL 10 (10) 10 (10) 10 (10) 10 (5–10) 5 (5) 10 (10) 5 (5) 5 (5)
232INH 0.016 (0.016) 0.016 (0.016) 0.016 (0.016) 0.016, 0.031a 0.031 (0.031) 0.031 (0.031) 0.031 (0.031) 0.031 (0.031)
232CHL 10 (10) 10 (10) 10 (10) 10 (5–10) 10 (10) 10 (10) 5 (5–10) 5 (5–10)
355INH 0.125 (0.125) 0.062 (0.062) 0.062 (0.062) 0.062 (0.062) 0.062 (0.062) 0.062 (0.062) 0.125 (0.125) 0.125 (0.125)
355CHL 10 (10) 5 (5–10) 5 (5–10) 5 (5) 10 (5–10) 10 (10) 2.5 (2.5–5) 5 (2.5–5)
INH, isoniazid; CHL, chloramphenicol.
Results for REMA were read on day 9, whereas bioluminescence results were read at different times from day 2 to day 8.
Results are the median and range (minimum–maximum) of 2–3 independent experiments.
aEach value was obtained in one out of two experiments.
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luminescence from H37Rv hspFFluc were determined on days 0
and 7 (end of the experiment) since lysis of the macrophages
is required to do such measurements; whereas the biolumines-
cence produced by the bacterial luciferase was measured
throughout the experiment since no lysis is needed.
Antimycobacterial activity, measured as a drop in biolumines-
cence, for the two highest drug concentrations tested was
observed as early as 24 h post-infection when using the Lux re-
porter (Figure 3) or 7 days post-infection in the case of FFluc
(Figure 4). Although a similar trend was obtained with cfu
counts (Figures 3 and 4), 4 extra weeks were required for
bacterial growth. The dose–response curves that were fitted to
the data for isoniazid and chloramphenicol are shown in
Figures 3 and 4, and the EC90 values for the four antibiotics
tested are shown in Tables 6 and 7. Comparisons of log EC90
showed no significant differences between the results obtained
by cfu counts and by bioluminescence reading from H37Rv
LuxG13 on days 1, 2 and 4 for isoniazid and chloramphenicol,
or between cfu and bioluminescence on day 7 for levofloxacin
(Table 6). Although no significant differences were found
between results obtained by cfu counts and by luminescence
on day 4 for streptomycin, caution should be taken when inter-
preting these results, since a lot of variation was observed
among replicates, which resulted in very wide confidence inter-
vals (Table 6). Similarly, log EC90 calculated using biolumines-
cence from H37Rv hspFFluc was not significantly different from
that calculated using cfu for any of the antibiotics tested
(Table 7). Log EC90 values for the vector control strain H37Rv
hsp were not significantly different from those obtained for the
luminescent strains, with the exception of H37Rv hspFFluc and
chloramphenicol, with an EC90 value 2.5 times higher for the
control strain. This is most likely due to the high variation
observed for the control cfu (Table 7). In fact, in most cases
we have observed variability in cfu results, whereas results for
bioluminescence were more consistent. This variation could be
due to the inherent errors in making dilutions and plating cfu
for clumping bacteria, such as mycobacteria, and would
account for some of the discrepancies observed between cfu
and bioluminescence.
Discussion
Tuberculosis drug development is hampered by the slow growth
of M. tuberculosis. Bioluminescence, light produced by an
enzymatic reaction, constitutes a rapid and highly sensitive
measurement of cell metabolic function that can be used as
an indirect marker of cell viability in drug screening assays.
There have been numerous attempts to develop luciferase
assays for antimycobacterial drug testing.26–32 Initially, FFluc
was the preferred reporter and the methods developed were
able to obtain MIC values similar to those obtained by more
traditional methods, but in a shorter time.29–31,33 In two cases,
96-well plate or minitube formats were adapted, but the
measurement of bioluminescence still required steps involving
transferring samples to a new plate and adding the luciferin
substrate.31,33 More recent studies have focused on the use of
the bacterial luciferase LuxAB from V. harveyi, since it was
found to be brighter in mycobacteria and it uses a cheaper
substrate. For example, using LuxAB, Cho et al.27 developed aTa
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microplate assay to test antimicrobial agents against non-
replicating M. tuberculosis grown under low oxygen conditions.
Luminescence was measured after a 28 h recovery step with
oxygen and results correlated well with cfu plated before the
recovery step. Bioluminescence has also been used for drug
testing against Mycobacterium ulcerans, a mycobacterium that
requires up to 3 months to form colonies, shortening the assay
to only 14 days.32 In spite of the advantages of using LuxAB,
the extra steps needed to add the substrate were still a major
drawback, and a proper standardization and comparison to
more traditional methods was required.
In the present study, we have developed and standardized a
96-well microplate assay for drug testing in vitro using the lux
operon, which does not require the addition of substrate, and
FFluc, which requires the addition of D-luciferin. Initially,
luminescence was read daily and compared with REMA to find
the optimal incubation period. Optimal results were obtained in
3 days and the MIC varied by no more than one drug dilution
compared with REMA. The luciferase assay here developed is par-
ticularly easy when using the lux operon, since luminescence can
be read straight from the MIC plate without the need for any
extra manipulations. Although FFluc requires the addition of luci-
ferin before reading luminescence, we decided to also validate
this reporter, since it is brighter than Lux and can therefore be
useful when lower numbers of bacteria are being used, e.g. in
a 384-well microplate assay. Moreover, luciferin can be added
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Figure 3. Effect of isoniazid (INH) and chloramphenicol (CHL) on intracellular H37Rv LuxG13, as determined by bioluminescence reading (top graphs)
and by cfu counts (bottom graphs). Data are plotted as a function of time and as dose–response curve, and are the mean and standard deviation of
2–3 independent experiments.
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Figure 4. Effect of isoniazid (INH) and chloramphenicol (CHL) on intracellular H37Rv hspFFluc, as determined by bioluminescence reading and by cfu
counts. Data are plotted as a function of time and as dose–response curve, and are the mean and standard deviation of 2–3 independent
experiments.
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straight into the MIC plate on day 3, thus limiting the amount of
extra steps and avoiding the additional variability introduced by
pipetting errors while taking a sample.
We have taken a step further and have also explored the use
of bioluminescence to determine whether the mechanism of
action of a drug is bacteriostatic or bactericidal. To this end,
we measured the luminescence during and after exposing the
cells to antibiotics, since we reasoned that removal of the
antibiotic would not have an effect on the luminescence for
bactericidal drugs, whereas it would result in a recovery of light
production if the drug was bacteriostatic. The results obtained
with Lux confirmed our hypothesis and the MBC values calcu-
lated were very close to those found by the traditional method
of cfu plating. However, the assay did not work for FFluc, the
results were quite different from those obtained by cfu determin-
ation and a large variability was observed. This is likely to be due
to the extra errors introduced while taking samples for measur-
ing the luminescence of FFluc and it could be avoided by adding
the luciferin straight into the MBC plate, as suggested for the MIC
assay.
Lastly, we have also developed a 96-well luciferase assay
for testing drugs against intracellular bacteria residing
in macrophages. Using a lux-expressing strain to infect
macrophages, we have been able to measure the luminescence
over time and to plot the growth-inhibition kinetics of the
luminescence in the presence of different drug concentrations.
This was only possible because of the autoluminescent nature
of the Lux-expressing mycobacteria. Moreover, by fitting the
data to dose–response curves we were able to calculate the ef-
ficacy of the drugs in terms of EC90. We found that the results for
the luciferase assay were not statistically different from the
results obtained by cfu counts, and that they could be obtained
in just 1–4 days for isoniazid, chloramphenicol and streptomycin,
and 7 days for levofloxacin. In the case of isoniazid, chloram-
phenicol and streptomycin, the EC90 values obtained on day 7
were lower than those obtained by cfu counts, which is likely
related to a more rapid effect of the drug on bacterial metabol-
ism, and therefore light production, compared with cell viability
and colony formation. On the other hand, optimal results as
compared with cfu were only obtained on day 7 for levofloxacin.
This may be due to the mechanism of action of the quinolone
and/or to the poorer uptake of this drug by the macrophages.34
Other authors have also attempted to develop similar assays.
For example, Arain et al.11 usedM. tuberculosisandMycobacterium
bovis BCG expressing FFluc to infect THP-1macrophages in 48-well
plates. They tested isoniazid and rifampicin at two concentrations,
and measured the luminescence at different timepoints, which
involved lysis of the macrophages. Although a decrease in
luminescence versus time could be observed, they did not calcu-
late the efficacy, nor did they compare the results obtained with
the traditional cfu plating method. Deb et al.10 conducted a
similar study with Mycobacterium aurum expressing FFluc. In this
Table 6. Drug activity against intracellular M. tuberculosis H37Rv LuxG13 and H37Rv hsp, expressed as EC90 (mg/L) and 95% confidence intervals
Drug
Bioluminescence cfu
day 1 day 2 day 4 day 7 LuxG13 hsp
INH 0.087a (0.059–0.128) 0.046a (0.034–0.063) 0.035a (0.027–0.046) 0.026 (0.023–0.029) 0.042 (0.031–0.056) 0.044 (0.026–0.076)
CHL 84.11a (19.09–370.6) 17.02a (11.66–24.85) 18.36a (6.28–53.66) 12.22 (6.04–24.73) 50.42 (8.98–283.1) 22.95 (8.55–61.57)
STR ambiguousb ambiguous 44.82a (2.75–731.4) 2.89 (2.19–3.79) 66.54 (0.26–17003) 59.2 (0.077–45514)
LVX ambiguous 3.099 (1.316–7.297) 1.547 (1.102–2.17) 1.023a (0.924–1.132) 0.878 (0.484–1.593) 1.708 (0.753–3.876)
INH, isoniazid; CHL, chloramphenicol; STR, streptomycin; LVX, levofloxacin.
Results represent two or three combined experiments.
aNo significant difference compared with H37Rv LuxG13 cfu (P.0.05).
bAmbiguous is a term coined by GraphPad meaning that the fit does not allow interpretation of the best-fit values.
Table 7. Drug activity against intracellular M. tuberculosis H37Rv hspFFluc and H37Rv hsp, expressed as EC90 (mg/L) and 95% confidence intervals
Drug Bioluminescence (day 7)
cfu
hspFFluc hsp
INH 0.023a (0.017–0.031) 0.042 (0.017–0.1) 0.028 (0.016–0.048)
CHL 3.686a (1.264–10.75) 11.56 (8.589–15.55) 28.36 (11.08–72.57)
STR 2.035a (0.875–4.734) 1.304 (0.451–3.774) 3.305 (0.578–18.91)
LVX 1.424a (0.713–2.845) 2.498 (2.059–3.03) 3.417 (1.506–7.752)
INH, isoniazid; CHL, chloramphenicol; STR, streptomycin; LVX, levofloxacin.
Results represent two or three combined experiments.
aNo significant difference compared with H37Rv hspFFluc cfu (P.0.05).
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case a decrease in both cfu and RLU could be observed both in vitro
and inside macrophages, but again the efficacy was not
calculated. More recently, Eklund et al.26 developed a method to
assessM. tuberculosis growth in humanmonocyte-derivedmacro-
phages in 96-well platesusing LuxAB. Theyproved that therewas a
good correlation between cfu and RLU, and then tested the
effect of drug treatment on the bioluminescence production of
M. tuberculosis growing intracellularly. However, only one drug
concentration was tested, which did not allow dose–response
curves to be plotted or efficacy calculated.
We have also optimized the macrophage luciferase assay
using FFluc. In this case, the luminescence was only read at
the end of the experiment, on day 7, since addition of the sub-
strate was required. Although the macrophages were lysed
prior to adding luciferin, lysis is not strictly necessary, since
macrophages are permeable to luciferin, although the amount
of luminescence obtained is lower than with lysis (data not
shown). We have found that permeability, and therefore light
production, depends on the buffer used to prepare the luciferin,
with the best results obtained when using 0.1 M sodium citrate
at pH 5. While this circumvents the need for lysis, it would still
make it an endpoint measurement, since the macrophages are
adversely affected by exposure to low pH. Nevertheless, using
FFluc, the antibiotics’ efficacy inside macrophages was deter-
mined in just 7 days, with results comparable to those obtained
by cfu plating.
In conclusion, we have developed a simple and rapid method
for screening antimycobacterial drugs in culture and in
macrophages. The results are comparable to those obtained
with conventional methods, but with a much shorter turnaround.
In addition, the use of autoluminescent bacteria facilitates the
determination of growth and inhibition kinetics. The methods
presented here are cost-effective, can easily be adapted to a
larger scale and are amenable to automation. Current efforts
are directed towards applying this technology to drug screening
in vivo.
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